We recently published an article titled These 10 Companies Led Monday’s Downturn. In this article, we are going to take a ...

Viking Therapeutics VKTX has outperformed the market over the past 5 years by 22.07% on an annualized basis producing an ...

We recently published a list of 15 Stocks That Took a Nosedive in January. In this article, we are going to take a look at ...

Check the time stamp on this data. Updated AI-Generated Signals for Viking Therapeutics Inc. (VKTX) available here: VKTX.

Equities researchers at William Blair decreased their Q1 2025 earnings per share estimates for shares of Viking Therapeutics in a research note issued to investors on Wednesday, February 5th. William ...

B. Riley lowered the firm’s price target on Viking Therapeutics (VKTX) to $96 from $109 and keeps a Buy rating on the shares.

Viking Therapeutics' fourth-quarter earnings miss estimates. The decline in stock price was attributable to a lack of material updates on its pipeline.

Viking Therapeutics is a clinical-stage biotech company focused on developing weight-loss therapies. Read why I rate VKTX ...

Citi analyst David Lebowitz initiated coverage of Viking Therapeutics (VKTX) with a Neutral rating and $38 price target Viking’s VK2735 is an ...

Trading Advice for Viking Therapeutics Inc. VKTX including day trading swing trading and long term investing plans for VKTX ...